Skip to main content
Category

News

News

Optimapharm announces EUCROF webinar presentation

Person-Centric Clinical Trials - Webinar Optimapharm announces Ana Stojković as a speaker at the EUCROF webinar - Person-Centric Clinical Trials.  Optimapharm is delighted to share that our VP of Clinical Operations - Ana Stojković, will be one of the speakers…
Marie Garchon
October 3, 2022
News

Optimapharm Conference Attendance in Q3 & Q4 of 2022

Optimapharm Announces Conferences Attendance in Q4 of 2022 Optimapharm d.o.o. (“Optimapharm”), a leading European, mid-sized, full-service Clinical Research Organization (CRO), is pleased to announce its attendance at conferences in Q4 of 2022. BIO EUROPE 2022 BIO-Europe has a long track…
Marie Garchon
September 28, 2022
News

Optimapharm Announces Acquisition of Qualitis SA

Optimapharm Announces Acquisition of Qualitis SA We Deliver on Your Promises Optimapharm d.o.o. (“Optimapharm”), a leading European, mid-sized, full-service Clinical Research Organization (CRO), is pleased to announce the acquisition of Qualitis SA (“Qualitis”). This acquisition will complement Optimapharm’s geographic coverage…
Marie Garchon
June 27, 2022
News

Taiga Biotechnologies important milestone

Taiga Biotechnologies important milestone Reaching a milestone Optimapharm is pleased to announce we have reached an important milestone on Taiga Biotechnologies Inc. TBX-2400-01 study initiating first site in Croatia for patients undergoing hematopoietic stem cell transplant (HSCT). #teamOptimapharm is excited…
info@rolandkoves.design
November 29, 2021
“

I would like to thank you all for the tremendous work done to reach this important milestone for the study in a very challenging and complex global environment. It is the first of many others that we will have to achieve together. Let's keep it up!

Clinical Project Leader, Big Pharma Company
“

We are very grateful for your hard work and dedication over the past few years. We are delighted to be part of this partnership and look forward to start treating patients in this new therapeutic area soon. We could not have done this without your contribution. We are very excited about the path ahead and can hardly wait to start this study.

Chief Executive Officer, Biotech Company
“

Corporate team and I would like to sincerely thank all the team members, both global and local, as well as the site staff, who have worked extremely hard to reach this lock! This has been achieved under difficult circumstances, being significantly earlier than planned for this discontinued study and in the middle of the COVID-19 pandemic with lockdowns or curfews in place in many of the countries. A huge thank you to all for your team spirit and commitment to reach this goal!

Clinical Project Lead, Big Pharma Company
“

Very pleased. Looking forward to getting the country up and running soon.

VP Global Clinical Operations, Medical Device Company

Let's talk about your study needs 

REQUEST PROPOSAL
Privacy policy »
Online privacy policy »
GDPR information »
Cookie policy »
Corporate information »
Head Office
Almeria Business Tower
Ulica grada Vukovara 284
10000 Zagreb, Croatia
T: +385-1-560 3600
© 2023 Optimapharm.
All rights reserved
Interested in a career with us?
View current opportunities »

 

Connect with us »
Optimapharm